Skip to main content
European Commission logo print header

High throughput vaccine evaluation

Objetivo

Synthetic peptide vaccines are going to play a major role in the development of new therapeutic vaccines and an increasing role in preventive vaccines. Peptide vaccine development requires however screening of large sets of peptides to arrive at the desired peptide (or peptide like) antigen that can be used in the final vaccine. Because out of a vast amount of lead peptides, the ones that induce cross reaction with the target protein need to be selected, vast numbers of animal's tests are needed. This requires an enormous number of animals that must be kept during a very long time incurring tremendous cost. Effectively this blocks fast and systematic synthetic peptide vaccine developments. We propose to develop a new alternative procedure to select systematically out of a large set of candidate peptides the ones that induce the appropriate antibody response. This procedure is based on the assessment of specificity of antibodies that occur at a very early stage of the immune response against a peptide by measuring the emerging antibodies on antibody forming cells for their ability to bind the peptide (as expected) and the native protein (desired). Because this is key information that can be measured at an early stage, it will allow very early selection of the appropriate immunogen. Instead of months involving a few peptides the selection can be done in a few weeks involving many peptides; i.e. true high throughput vaccine development at fraction of the cost.

Tema(s)

Data not available

Convocatoria de propuestas

Data not available

Régimen de financiación

BUR - Bursaries, grants, fellowships

Coordinador

PEPSCAN SYSTEMS B.V.
Aportación de la UE
Sin datos
Dirección
Edelhertweg 15
8203 AB LELYSTAD
Países Bajos

Ver en el mapa

Coste total
Sin datos